-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $633

Benzinga·11/04/2026 23:44:44
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $612 to $633.